Literature DB >> 18981891

Advanced magnetic resonance imaging of cerebral cavernous malformations: part II. Imaging of lesions in murine models.

Robert Shenkar1, Palamadai N Venkatasubramanian, Alice M Wyrwicz, Jin-cheng Zhao, Changbin Shi, Amy Akers, Douglas A Marchuk, Issam A Awad.   

Abstract

OBJECTIVE: We sought to assess the appearance of cerebral cavernous malformations (CCM) on magnetic resonance imaging (MRI) scans in murine Ccm1 and Ccm2 gene knockout models and to develop a technique of lesion localization for correlative pathobiological studies
METHODS: Brains from 18 CCM mutant mice (Ccm1 Trp53 and Ccm2 Trp53) and 28 control animals were imaged by gradient recalled echo (T2*)-weighted MRI scans at 4.7- and 14.1-T in vivo and/or ex vivo. After MRI scanning, the brains were removed and stained with hematoxylin and eosin, and cells were laser-microdissected for molecular biological studies.
RESULTS: T2*-weighted MRI scans of brains in vivo and ex vivo revealed lesions similar to human CCMs in mutant mice, but not in control animals. Stereotactic localization and hematoxylin and eosin staining of correlative tissue sections confirmed lesion histology and revealed other areas of dilated capillaries in the same brains. Some lesions were identified by MRI scans at 14.1-T, but not at 4.7-T. Polymerase chain reaction amplification from Ccm1 and beta-actin genes was demonstrated from nucleic acids extracted from laser microdissected lesional and perilesional cells.
CONCLUSION: The high-field MRI techniques offer new opportunities for further investigation of disease pathogenesis in vivo, and the localization, staging, and histobiological dissection of lesions, including the presumed earliest stages of CCM lesion development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981891      PMCID: PMC2844241          DOI: 10.1227/01.NEU.0000315862.24920.49

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  26 in total

1.  Ultrastructural pathological features of cerebrovascular malformations: a preliminary report.

Authors:  J H Wong; I A Awad; J H Kim
Journal:  Neurosurgery       Date:  2000-06       Impact factor: 4.654

2.  The in vitro effects of a bimodal contrast agent on cellular functions and relaxometry.

Authors:  Cecilie Brekke; Sarah C Morgan; Andrew S Lowe; Thomas J Meade; Jack Price; Steve C R Williams; Michel Modo
Journal:  NMR Biomed       Date:  2007-04       Impact factor: 4.044

3.  Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers.

Authors:  Yun Wu; Weibo Cai; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

4.  The role of small angiomatous malformations in the production of intracerebral hematomas.

Authors:  G MARGOLIS; G L ODOM; B WOODHALL; B M BLOOR
Journal:  J Neurosurg       Date:  1951-11       Impact factor: 5.115

Review 5.  [131 cases of cavernous angioma (cavernomas) of the CNS, discovered by retrospective analysis of 24,535 autopsies].

Authors:  P Otten; G P Pizzolato; B Rilliet; J Berney
Journal:  Neurochirurgie       Date:  1989       Impact factor: 1.553

6.  The MRI appearance of cavernous malformations (angiomas).

Authors:  D Rigamonti; B P Drayer; P C Johnson; M N Hadley; J Zabramski; R F Spetzler
Journal:  J Neurosurg       Date:  1987-10       Impact factor: 5.115

Review 7.  MR appearance of hemorrhage in the brain.

Authors:  W G Bradley
Journal:  Radiology       Date:  1993-10       Impact factor: 11.105

8.  Value of gradient-echo magnetic resonance imaging in the diagnosis of familial cerebral cavernous malformation.

Authors:  Fritz-Georg Lehnhardt; Ulrich von Smekal; Benedikt Rückriem; Werner Stenzel; Michael Neveling; Wolf-Dieter Heiss; Andreas H Jacobs
Journal:  Arch Neurol       Date:  2005-04

Review 9.  Imaging inflammation in acute brain ischemia.

Authors:  Sebastian Jander; Michael Schroeter; Andreas Saleh
Journal:  Stroke       Date:  2007-02       Impact factor: 7.914

10.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

View more
  24 in total

1.  Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice.

Authors:  Aubrey C Chan; Stavros G Drakos; Oscar E Ruiz; Alexandra C H Smith; Christopher C Gibson; Jing Ling; Samuel F Passi; Amber N Stratman; Anastasia Sacharidou; M Patricia Revelo; Allie H Grossmann; Nikolaos A Diakos; George E Davis; Mark M Metzstein; Kevin J Whitehead; Dean Y Li
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

Review 2.  Genetics of cerebral cavernous malformations: current status and future prospects.

Authors:  H Choquet; L Pawlikowska; M T Lawton; H Kim
Journal:  J Neurosurg Sci       Date:  2015-04-22       Impact factor: 2.279

3.  Mutations of RNF213 are responsible for sporadic cerebral cavernous malformation and lead to a mulberry-like cluster in zebrafish.

Authors:  Jing Lin; Jie Liang; Jun Wen; Man Luo; Jiaoxing Li; Xunsha Sun; Xiaowei Xu; Jianli Li; Dongxian Wang; Jie Wang; Huimin Chen; Rong Lai; Fengyin Liang; Chuan Li; Fei Ye; Jingjing Zhang; Jinsheng Zeng; Shulan Yang; Wenli Sheng
Journal:  J Cereb Blood Flow Metab       Date:  2020-04-04       Impact factor: 6.200

Review 4.  STRIPAK complexes: structure, biological function, and involvement in human diseases.

Authors:  Juyeon Hwang; David C Pallas
Journal:  Int J Biochem Cell Biol       Date:  2013-12-11       Impact factor: 5.085

5.  Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease.

Authors:  David A McDonald; Changbin Shi; Robert Shenkar; Rebecca A Stockton; Feifei Liu; Mark H Ginsberg; Douglas A Marchuk; Issam A Awad
Journal:  Stroke       Date:  2011-10-27       Impact factor: 7.914

6.  RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.

Authors:  Robert Shenkar; Changbin Shi; Cecilia Austin; Thomas Moore; Rhonda Lightle; Ying Cao; Lingjiao Zhang; Meijing Wu; Hussein A Zeineddine; Romuald Girard; David A McDonald; Autumn Rorrer; Carol Gallione; Peter Pytel; James K Liao; Douglas A Marchuk; Issam A Awad
Journal:  Stroke       Date:  2016-11-22       Impact factor: 7.914

Review 7.  Biology of vascular malformations of the brain.

Authors:  Gabrielle G Leblanc; Eugene Golanov; Issam A Awad; William L Young
Journal:  Stroke       Date:  2009-10-15       Impact factor: 7.914

8.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

9.  Immune response in human cerebral cavernous malformations.

Authors:  Changbin Shi; Robert Shenkar; Hongyan Du; Edward Duckworth; Harish Raja; H Hunt Batjer; Issam A Awad
Journal:  Stroke       Date:  2009-03-12       Impact factor: 7.914

10.  Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease.

Authors:  Romuald Girard; Hussein A Zeineddine; Courtney Orsbon; Huan Tan; Thomas Moore; Nick Hobson; Robert Shenkar; Rhonda Lightle; Changbin Shi; Maged D Fam; Ying Cao; Le Shen; April I Neander; Autumn Rorrer; Carol Gallione; Alan T Tang; Mark L Kahn; Douglas A Marchuk; Zhe-Xi Luo; Issam A Awad
Journal:  J Neurosci Methods       Date:  2016-06-23       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.